Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,127 public posts
Filter results
Bipolar Androgen Therapy in Men With Metastatic Castration-Resistant Prostate Cancer After Progression on Enzalutamide
http://www.practiceupdate.com/content/bipolar-androgen-therapy-in-men-with-metastatic-
castration
-resistant-prostate-cancer-after-progression-on-enzalutamide/62093/61/11/1
http://www.practiceupdate.com/content/bipolar-androgen-therapy-in-men-with-metastatic-
castration
-resistant-prostate-cancer-after-progression-on-enzalutamide/62093/61/11/1
snoraste
in
Advanced Prostate Cancer
6 years ago
Folate & PCa recurrence in the CWR22 model.
KEYWORDS: androgen withdrawal;
castration
recurrent prostate cancer; folate; one-carbon metabolism; polyamine metabolism PMID: 29262598 PMCID: PMC5732764 DOI: 10.18632/oncotarget.21911 [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094800/
KEYWORDS: androgen withdrawal;
castration
recurrent prostate cancer; folate; one-carbon metabolism; polyamine metabolism PMID: 29262598 PMCID: PMC5732764 DOI: 10.18632/oncotarget.21911 [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094800/
pjoshea13
in
Advanced Prostate Cancer
7 years ago
ASCO Genitourinary Cancers Symposium [PROSPER].
/GU18-Prostate-Cancer-Localized-Disease.pdf -Patrick 3 Oral Abstract Session, Thu, 1:00 PM-2:30 PM and Poster Session (Board #A4), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic
castration
-resistant
/GU18-Prostate-Cancer-Localized-Disease.pdf -Patrick 3 Oral Abstract Session, Thu, 1:00 PM-2:30 PM and Poster Session (Board #A4), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic
castration
-resistant
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Low testosterone / PSA failure / risk of death.
i.e. partial
castration
. None of the studies published in the past 13 years have changed the view that it unsafe to be at the high end of hypogonadal, or the very low end of "normal".
i.e. partial
castration
. None of the studies published in the past 13 years have changed the view that it unsafe to be at the high end of hypogonadal, or the very low end of "normal".
pjoshea13
in
Advanced Prostate Cancer
7 years ago
ASCO Genitourinary Cancers Symposium (ARV7/AR ratio and neutrophil-to-lymphocyte ratio (NLR) as predictors of docetaxel benefit)
-Patrick 254 Poster Session (Board #M8), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM ARV7/AR ratio and neutrophil-to-lymphocyte ratio (NLR) as predictors of docetaxel benefit in metastatic
castration
-resistant prostate cancer patients (mCRPC).
-Patrick 254 Poster Session (Board #M8), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM ARV7/AR ratio and neutrophil-to-lymphocyte ratio (NLR) as predictors of docetaxel benefit in metastatic
castration
-resistant prostate cancer patients (mCRPC).
pjoshea13
in
Advanced Prostate Cancer
6 years ago
ED, LIBIDO, PUMPS and PILLS
Testicles shrunk, chemical
castration
. I thought Sex was now in the past for me. But I missed it. A lot. I didn't even think about sex for weeks. I am an experimenter by nature so I found a way to get some enjoyment back. I found that my libido was reignited by porn.
Testicles shrunk, chemical
castration
. I thought Sex was now in the past for me. But I missed it. A lot. I didn't even think about sex for weeks. I am an experimenter by nature so I found a way to get some enjoyment back. I found that my libido was reignited by porn.
steinmother
in
Prostate Cancer Network
7 years ago
thoughts from a newby
Maybe a dropdown menu to help beginners, something like: Abbreviations etc Clinical name first (abiraterone), brand name second (Zytiga) varies by country PCa prostate cancer ADT androgen deprivation therapy mCRPC metastatic
castration
-resistant Prostate Cancer mets metastases bicalutamide
Maybe a dropdown menu to help beginners, something like: Abbreviations etc Clinical name first (abiraterone), brand name second (Zytiga) varies by country PCa prostate cancer ADT androgen deprivation therapy mCRPC metastatic
castration
-resistant Prostate Cancer mets metastases bicalutamide
rpol
in
Advanced Prostate Cancer
6 years ago
"Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens."
However, the disease eventually progresses and develops resistance to ADT in majority of the patients, leading to the emergence of metastatic
castration
-resistant prostate cancer (mCRPC).
However, the disease eventually progresses and develops resistance to ADT in majority of the patients, leading to the emergence of metastatic
castration
-resistant prostate cancer (mCRPC).
JLS1
in
Advanced Prostate Cancer
6 years ago
Estrogen and Androgen Blockade for Advanced PCa.
Abstract Androgen deprivation therapy (ADT) has been widely prescribed for patients with advanced prostate cancer (PC) to control key signaling pathways via androgen receptor (AR) and AR-collaborative transcriptional factors; however, PC gradually acquires a lethal phenotype and results in
castration
-resistant
Abstract Androgen deprivation therapy (ADT) has been widely prescribed for patients with advanced prostate cancer (PC) to control key signaling pathways via androgen receptor (AR) and AR-collaborative transcriptional factors; however, PC gradually acquires a lethal phenotype and results in
castration
-resistant
pjoshea13
in
Advanced Prostate Cancer
6 years ago
How Useful is the Circulating Tumor Cell [CTC] count?
"Purpose Measures of response that are clinically meaningful and occur early are an unmet need in metastatic
castration
-resistant prostate cancer clinical research and practice.
"Purpose Measures of response that are clinically meaningful and occur early are an unmet need in metastatic
castration
-resistant prostate cancer clinical research and practice.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide.
Further studies with BAT are needed to define the potential clinical role for BAT in the management of metastatic
castration
-resistant prostate cancer and the optimal strategy for sequencing between androgen and antiandrogen therapies in metastatic
castration
-resistant prostate cancer to maximise therapeutic
Further studies with BAT are needed to define the potential clinical role for BAT in the management of metastatic
castration
-resistant prostate cancer and the optimal strategy for sequencing between androgen and antiandrogen therapies in metastatic
castration
-resistant prostate cancer to maximise therapeutic
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Supraphysiologic Testosterone Therapy for PCa. BAT.
In this regard
castration
resistant VCaP cells treated with sequentially higher T doses had less significant apoptotic responses to androgen withdrawal than those seen in VCaP cells exposed to a single high T “boost”." ...
In this regard
castration
resistant VCaP cells treated with sequentially higher T doses had less significant apoptotic responses to androgen withdrawal than those seen in VCaP cells exposed to a single high T “boost”." ...
pjoshea13
in
Advanced Prostate Cancer
7 years ago
The War on Cancer, & Stem-like Cancer Cells.
The big success stories of recent years - Zytiga & Xtandi - follow in the Huggins tradition by targeting the androgen receptor [AR], either directly (as with Casodex, & now Xtandi) or by starving AR of hormones (as with
castration
, DES, Lupron, & now Zytiga). Alas, PCa progenitor cells lack AR.
The big success stories of recent years - Zytiga & Xtandi - follow in the Huggins tradition by targeting the androgen receptor [AR], either directly (as with Casodex, & now Xtandi) or by starving AR of hormones (as with
castration
, DES, Lupron, & now Zytiga). Alas, PCa progenitor cells lack AR.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Integrating evolutionary dynamics into treatment of mCRPC.
Castration
continues well into the off-phase, according to Freedland. In addition, the first on-phase is often a year, by which time only "bad" cells are present. If T were to be supplemented in the off phase-of IADT, after a much shorter on-phase, we would expect to see some reset activity.
Castration
continues well into the off-phase, according to Freedland. In addition, the first on-phase is often a year, by which time only "bad" cells are present. If T were to be supplemented in the off phase-of IADT, after a much shorter on-phase, we would expect to see some reset activity.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Xtandi (Enzalutamide) & Drug-Drug Interaction.
[Epub ahead of print] Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic
Castration
Resistant Prostate Cancer (mCRPC) Patients.
[Epub ahead of print] Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic
Castration
Resistant Prostate Cancer (mCRPC) Patients.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
My life as of right now
To a certain level this is
castration
it just that I take some other pills which help a little.
To a certain level this is
castration
it just that I take some other pills which help a little.
Alessia
in
Fertility Network UK
7 years ago
Estrogen receptor signaling in prostate cancer.
The ERβ is generally retained in hormone naïve and metastatic prostate cancer, but is partially lost in
castration
resistant disease.
The ERβ is generally retained in hormone naïve and metastatic prostate cancer, but is partially lost in
castration
resistant disease.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
"Role of PARP Inhibitors Clarified in Prostate Cancer"
worth sharing: Role of PARP Inhibitors Clarified in Prostate Cancer Ariela Katz Published Online: May 22,2017 http://www.targetedonc.com/publications/targeted-therapy-news/2017/may-2017/role-of-parp-inhibitors-clarified-in-prostate-cancer Our understanding of the genomic landscape of metastatic
castration
-resistant
worth sharing: Role of PARP Inhibitors Clarified in Prostate Cancer Ariela Katz Published Online: May 22,2017 http://www.targetedonc.com/publications/targeted-therapy-news/2017/may-2017/role-of-parp-inhibitors-clarified-in-prostate-cancer Our understanding of the genomic landscape of metastatic
castration
-resistant
JLS1
in
Advanced Prostate Cancer
6 years ago
Abiraterone acetate with/out LHRH therapy.
"The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in
castration
-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking." ???
"The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in
castration
-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking." ???
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Androgen Receptor Pathway-Independent PCa.
Castration
or DES treatment mostly fails within 18 to 24 months, but with late diagnosis & high male mortality rates from other causes, compared to today, Huggins must have seemed like a hero. {In 1950, The PCa mortality rate in the U.S. was 28.6 per 100,000 lives.
Castration
or DES treatment mostly fails within 18 to 24 months, but with late diagnosis & high male mortality rates from other causes, compared to today, Huggins must have seemed like a hero. {In 1950, The PCa mortality rate in the U.S. was 28.6 per 100,000 lives.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
1
...
50
51
52
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1004 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest